Agreed, captainblood,
A particularly encouraging note in the announcement is this:
Ellume’s Founder and Chief Executive Officer Sean Parsons said: “Anteo has been a terrific development partner for Ellume and we look forward to building upon this relationship as we head into the commercialisation phase of the business. The Anteo team have a deep understanding of the industry and their technology, which makes them an excellent partner for developers and manufacturers of diagnostic products.”
I understand that we have had a good working relationship with Ellume, but that is fulsome praise indeed, that will not be lost on GSK or Quiagen. One can imagine their scientists not directly involved with Ellume have already asked the question, "so what is so good about Ellume? . . . . Oh, we'd better take a look at this AnteoBind, then."
This announcement has far more substance than the initial PoC1 (Phillips) announcement. Yes, no potential income figures, but they would be highly conjectural and of little value. More significant is this: "It is pleasing to see the transformation of our partnership from R&D to near-term commercialization opportunities."
"near term" - good to see that.
Yep, made my day!
